Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sm-TSP-2 Vaccine Phase I Study
NCT02337855Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Feb 2015
- Primary completion
- Jan 2017
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Sm-TSP-2 in schistosomiasis mansoni (9 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Occurrence of new-onset chronic medical conditions (including AESI) at Day 478, Occurrence of solicited injection site reactogenicity and 3 more. Started Feb 2015; status: completed.
02
Drugs
Sm-TSP-2
03
Conditions
schistosomiasis mansoni
Beyond the preview
Go deeper on NCT02337855.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02337855.